Background & relevance
Adjuvant (postoperative) endocrine therapy is a major treatment strategy for HR-positive, HER2-negative early breast cancer. Questions remain: which type? Optimal duration? Should chemotherapy be added?
Tumours are grouped into surrogate intrinsic subtypes based on routine histology and immunohistochemistry data . In this course, only patients with luminal A and luminal B and HER2-negative disease are included.
- Cardoso F, Kyriakides S, Ohno S, et al. Ann Oncol 2019;30:1194-220. PubMed